单独使用阿卡拉布鲁丁尼布或与叶囊淋巴瘤治疗的瑞图西玛结合使用:一项开放标签研究
Paolo Strati1, Rebecca Champion2, Morton Coleman3
1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
British journal of haematology
|September 23, 2024
概括
阿卡拉布鲁丁尼是一种向治疗,在治疗毛囊性淋巴瘤 (FL) 中表现有前途. 单独的acalabrutinib和与rituximab结合的acalabrutinib在复发性/耐药性和未经治疗的FL患者中表现出活性和良好的耐受性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 毛囊性淋巴瘤 (FL) 是一种常见的B细胞非霍奇金淋巴瘤.
- 复发性/耐药性 (R/R) 和未经治疗的 (TN) FL需要有效的治疗选择.
研究的目的:
- 评估acalabrutinib单一治疗和acalabrutinib加 rituximab在FL患者的安全性和疗效.
- 评估acalabrutinib在R/R和TN FL群体中的活性.
主要方法:
- 开放标签,并行组研究设计.
- 随机选择R/R FL患者接受acalabrutinib或acalabrutinib加 rituximab.
- 包括接受acalabrutinib加 rituximab的TN FL队列.
主要成果:
- 在TNFL中,甲拉布鲁丁尼和修复药显示出高的整体应答率 (92.3%) 和持久的缓解 (>4年).
- 在R/R和TNFL患者中,这两种治疗方案都耐受良好.
- 阿卡拉布鲁丁尼单一治疗显示在R/R FL中具有活性.
结论:
- 单独使用或与rituximab结合使用的acalabrutinib是一种耐受性良好且有效的卵泡淋巴瘤治疗方法.
- 需要对FL中的acalabrutinib进行进一步的调查.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.0K
相关概念视频
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
